StimCardio Raises $30M Series A for Wearable AF Therapy

A patient wearing StimCardio Medical's Rhyvive device would carry part of the treatment routine home after catheter ablation. That is the development proposition behind the Los Angeles company's $30M Series A: investigate whether stimulation delivered at the wrist can help improve the period after an atrial fibrillation procedure, when care depends increasingly on what happens outside the hospital.

StimCardio announced the oversubscribed financing on October 29, 2026. John Slump's Metis MedTech led the round, with Catalyst Health Ventures, unnamed corporate strategic investors and other new and existing investors participating. The company expects the proceeds to support its planned NeuroPulse 2 multicenter pivotal study and preparation for an FDA De Novo submission.

For medical-device investors, the opportunity sits in the relationship between a procedure and its follow-through. StimCardio is developing a therapeutic wearable intended to complement ablation, with the patient participating in a routine beyond the procedure room. Rhyvive remains investigational, has no regulatory clearance or approval, and is unavailable for sale.

What StimCardio's Series A is financing

StimCardio's financing follows a pilot clinical program and commits resources to a more demanding stage of development. A pivotal study is meant to provide evidence on a scale that can inform a regulatory assessment. Preparation for a De Novo submission is part of the company's stated plan; the announcement gives no approval date or guarantee of a regulatory outcome.

CEO Amir Soltanianzadeh leads the company alongside founder and CSO Amos Ziv and co-founder and CTO Tsahi Holand. The current leadership page places the business across Los Angeles headquarters, an Austin technology center and scientific operations in Tel Aviv. That distribution reflects the disciplines a therapeutic wearable has to bring together: clinical investigation, device engineering, physiological measurement and the practical business of developing a regulated product.

Metis founder John Slump and Catalyst managing partner Joshua Phillips both serve on StimCardio's board. Their participation gives the round an operating connection to the company as it advances its clinical program. The announcement does not disclose valuation or identify all participating strategic investors, and the $30M should be read as the announced Series A closing amount rather than an independently established lifetime funding total.

How Rhyvive fits into atrial fibrillation care

Rhyvive is designed to stimulate the median nerve non-invasively at the wrist, targeting autonomic pathways involved in cardiac rhythm. StimCardio's initial development focus is use after catheter ablation for atrial fibrillation, or AF. The company is investigating an adjunct to an existing intervention, so its proposed place in care depends on demonstrating what the added treatment contributes.

The technology description combines electrical and optical sensing with stimulation, a patient application and cloud-based analysis. StimCardio describes a closed-loop architecture intended to inform personalization from physiological information over time. These are development capabilities and intentions, and the description should not be mistaken for an approved indication or a commercially validated autonomous treatment system.

The commercial question follows the clinical design. A treatment used at home introduces a continuing relationship among the patient, the device and the clinical team interpreting the information around it. Instructions, adherence and usable data become part of the work needed to deliver the proposed benefit. For founders and investors, that widens the product assignment beyond building hardware that can deliver a stimulus.

What the NEUROPULSE pilot actually found

The NEUROPULSE pilot published in Heart Rhythm provides the central clinical context for the financing. It was a randomized, double-blind, sham-controlled study across 3 centers. Researchers randomized 77 patients, with 59 included in the modified intention-to-treat analysis: 31 receiving active median nerve stimulation and 28 receiving sham treatment.

Active stimulation was associated with fewer recurrent atrial arrhythmia events during follow-up. A particularly high event count in 1 sham patient influenced the overall comparison; an analysis excluding that patient still found a statistically significant difference in event counts. This makes the endpoint worth understanding in its own terms, rather than reducing the study to a single promotional percentage.

Six-month arrhythmia-free survival was 90.0% in the active group and 80.8% in the sham group, and that difference was not statistically significant. The number of episodes and the number of people experiencing a recurrence describe related but different outcomes. The study's authors called for confirmation in an adequately powered trial, which is why the financing's planned pivotal-study assignment matters to the business story.

The patient routine becomes part of development

StimCardio's clinical research program includes feasibility, pilot and mechanism-focused investigations. That breadth gives the company several ways to examine its approach, while each study retains a specific question and population. Evidence from one setting should travel into another through a justified clinical argument, rather than through the convenience of a platform description.

For the wider wearable-device market, StimCardio illustrates how different a therapeutic proposition can be from recording information for a user. The desired outcome places demands on clinical evidence and on the treatment routine that produces that evidence. A device can collect useful signals while the therapeutic question still needs a carefully designed comparison.

The Series A finances work inside that relationship. As StimCardio prepares NeuroPulse 2, its researchers, engineers and clinical teams will be developing both the intervention and the evidence physicians need to assess it. The patient's week after ablation remains central to that assignment, carrying the company's idea from the procedure room into the conditions in which it is intended to be used.